Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) FCF Margin % : 65.34% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Clinuvel Pharmaceuticals's Free Cash Flow for the six months ended in Dec. 2023 was $14.11 Mil. Clinuvel Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was $21.59 Mil. Therefore, Clinuvel Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 65.34%.

As of today, Clinuvel Pharmaceuticals's current FCF Yield % is 4.97%.

The historical rank and industry rank for Clinuvel Pharmaceuticals's FCF Margin % or its related term are showing as below:

CLVLF' s FCF Margin % Range Over the Past 10 Years
Min: -218.73 Med: 43.22 Max: 60.01
Current: 44.71

During the past 13 years, the highest FCF Margin % of Clinuvel Pharmaceuticals was 60.01%. The lowest was -218.73%. And the median was 43.22%.

CLVLF's FCF Margin % is ranked better than
96.52% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs CLVLF: 44.71

Clinuvel Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Clinuvel Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals FCF Margin % Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

58.62

40.84

38.37

60.01

45.82

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															70.11	53.95	70.27	31.16	65.34

Competitive Comparison of Clinuvel Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's FCF Margin % falls into.

Clinuvel Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Clinuvel Pharmaceuticals's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	24.083	/	52.564
	=	45.82 %

Clinuvel Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	14.108	/	21.591
	=	65.34 %

Clinuvel Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.